Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence.
Hong Kong
antipsychotic agents
paliperidone palmitate
patient compliance
schizophrenia
Journal
CNS neuroscience & therapeutics
ISSN: 1755-5949
Titre abrégé: CNS Neurosci Ther
Pays: England
ID NLM: 101473265
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
entrez:
8
2
2021
pubmed:
9
2
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Recent research on second-generation long-acting injectable antipsychotics (LAI SGAs) has proven its effectiveness in minimizing medication nonadherence problem and reducing relapses. Administered by medical professionals, making quick detection of nonadherence possible, long-acting injectable antipsychotics (LAIs) facilitate immediate intervention and recovery process, and thus are favored by psychiatrists. Despite a higher initial cost with LAIs, the subsequent schizophrenia-related health costs for hospitalizations and outpatients are greatly reduced. With reference to guidelines published by psychiatric associations around the globe, this article looks at scenarios in Hong Kong on the management of severe mentally ill patients with regard to the use of a host of psychosocial interventions as well as LAI SGAs as a preferable treatment. In particular, it examines the benefits of using LAI SGAs for Hong Kong patients who demonstrated high nonadherence treatment rates due to their social environment. It assesses the rationale behind the early usages of LAI SGAs, which help to provide better recovery outcomes for patients.
Identifiants
pubmed: 33555616
doi: 10.1111/cns.13375
pmc: PMC7869929
doi:
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
12-19Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021 The Authors. CNS Neuroscience & Therapeutics Published by John Wiley & Sons Ltd.
Références
Schizophr Res Treatment. 2012;2012:962371
pubmed: 22970366
CNS Neurosci Ther. 2021 Mar;27 Suppl 1:12-19
pubmed: 33555616
Schizophr Res Treatment. 2012;2012:560836
pubmed: 22966439
Hong Kong Med J. 2015 Apr;21 Suppl 2:27-31
pubmed: 25852099
Postgrad Med J. 2002 Jul;78(921):383-4
pubmed: 12151651
Asia Pac Psychiatry. 2016 Jun;8(2):154-71
pubmed: 27062665
BMC Psychiatry. 2013 Sep 10;13:221
pubmed: 24016390
Asian J Psychiatr. 2014 Dec;12:163-9
pubmed: 25440570
Expert Opin Drug Saf. 2010 Sep;9(5):683-97
pubmed: 20690885
CNS Spectr. 2007 Oct;12(10 Suppl 17):21-6
pubmed: 17934386
Curr Opin Psychiatry. 2009 Jul;22(4):374-80
pubmed: 19417668
Schizophr Res. 2008 Mar;100(1-3):60-9
pubmed: 18255269
Oman Med J. 2011 May;26(3):155-9
pubmed: 22043406
J Psychiatr Ment Health Nurs. 2005 Apr;12(2):237-44
pubmed: 15788043
Psychol Med. 1983 Feb;13(1):177-83
pubmed: 6133297
Neuropsychopharmacology. 1996 Mar;14(3 Suppl):13S-21S
pubmed: 8866739
Early Interv Psychiatry. 2016 Oct;10(5):365-77
pubmed: 26403538
Prim Care Companion J Clin Psychiatry. 2009;11(4):147-54
pubmed: 19750066
J Clin Psychiatry. 2007;68 Suppl 14:27-30
pubmed: 18284275
Neuropsychiatr Dis Treat. 2013;9:1163-70
pubmed: 23976858
P T. 2014 Sep;39(9):638-45
pubmed: 25210417
Arch Psychiatr Nurs. 2016 Oct;30(5):552-7
pubmed: 27654236
Neuropsychol Rehabil. 2018 Jun;28(4):602-613
pubmed: 27219068
J Ment Health. 2015 Apr;24(2):103-10
pubmed: 25643043
J Psychiatr Ment Health Nurs. 2008 Nov;15(9):758-66
pubmed: 18844802
World Psychiatry. 2014 Feb;13(1):12-20
pubmed: 24497237
Ther Adv Psychopharmacol. 2015 Dec;5(6):339-50
pubmed: 26834967
Schizophr Bull. 1998;24(1):99-113
pubmed: 9502549
Schizophr Bull. 1998;24(1):75-85
pubmed: 9502547
Arch Gen Psychiatry. 1999 Mar;56(3):241-7
pubmed: 10078501
Am J Psychiatry. 2013 Jun;170(6):609-15
pubmed: 23558429
Health Qual Life Outcomes. 2012 Jan 31;10:15
pubmed: 22289443
Neuropsychiatr Dis Treat. 2013;9:1463-81
pubmed: 24109184
J Gen Intern Med. 2012 Oct;27(10):1361-7
pubmed: 22618581
Psychiatr Serv. 2007 Apr;58(4):437
pubmed: 17412839
J Med Internet Res. 2016 Apr 22;18(4):e92
pubmed: 27105939
Neuropsychopharmacology. 2007 Oct;32(10):2057-66
pubmed: 17327887
Int J Psychiatry Clin Pract. 2011 Nov;15(4):286-95
pubmed: 22122003
Neuropsychiatr Dis Treat. 2011;7:93-101
pubmed: 21552311
Br J Psychiatry. 1981 Jun;138:490-4
pubmed: 6117347
BMJ. 2010 Aug 19;341:c4024
pubmed: 20724402
BMC Psychiatry. 2013 Oct 16;13:261
pubmed: 24131801
Psychiatry Res. 2005 Jun 15;135(2):103-11
pubmed: 15923043
Schizophr Res. 2000 May 5;42(3):241-7
pubmed: 10785582
Ther Clin Risk Manag. 2007 Dec;3(6):1047-58
pubmed: 18516274
Psychiatr Danub. 2012 Sep;24 Suppl 1:S95-9
pubmed: 22945197
Br J Psychiatry. 2011 Dec;199(6):445-52
pubmed: 22130746
Patient Relat Outcome Meas. 2014 Jun 23;5:43-62
pubmed: 25061342
Nurse Educ Today. 2013 Sep;33(9):969-75
pubmed: 23182892
World Psychiatry. 2017 Jun;16(2):146-153
pubmed: 28498575
Patient Prefer Adherence. 2011 Mar 21;5:165-71
pubmed: 21573047
J Behav Health Serv Res. 2013 Jul;40(3):355-66
pubmed: 23579871
Eur Psychiatry. 2014 Nov;29 Suppl 2:1409-13
pubmed: 25455704